

November 11, 2022

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-audited Financial Results for the quarter and half year ended September 30, 2022.

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 11th November 2022 at the Registered Office of the company have considered and approved the Un-audited Financial Results for the quarter and half year ended September 30, 2022. In this regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter and half year ended September 30, 2022.
2. Limited Review Report from the auditor for the quarter and half year ended September 30, 2022.

You are requested to kindly take the same on record.

Thanking You
Yours Truly,
For Ajooni Biotech Limited
Jasjit Singh
Managing Director
DIN: 01937631




AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2022 (In Lakhs)


PARTICULARS	Quarter Ended				Year Ended (Audited)
	30.09.2022	30.06.2022	30.09.2021	Period Ended (UnAudited) 30.09.2022	Period Ended (UnAudited) 30.09.2021
I Income					
Revenue from operations	1,029.14	1,231.07	1,839.19	2,260.21	3,423.81
Other income	0.34	0.78	0.81	1.12	1.73
Total income from operations	1,029.48	1,231.85	1,840.00	2,261.33	3,425.54
II Expenses					
Cost of Material Consumed	767.05	1,072.05	1,562.05	1,839.10	2,904.87
Change In Inventories	55.98	(42.22)	(15.22)	13.76	(16.71)
Employee benefit expenses	45.86	52.45	42.03	98.31	80.13
Finance costs	13.38	9.92	22.18	23.30	35.48
Depreciation and amortization expenses	25.32	24.94	28.86	50.26	47.80
Payment to NSE				-	
Other expenses	101.63	72.62	154.81	174.25	287.89
Total expenses	1,009.22	1,189.76	1,794.71	2,198.98	3,339.46
Profit/(Loss) before exceptional items and tax	20.26	42.09	45.29	62.35	86.08
Exceptional items					
Profit/(Loss) before tax	20.26	42.09	45.29	62.35	86.08
Tax expenses					
a) Current tax	5.27	10.94	11.78	16.21	22.28
b) Deferred tax	0.55	1.05	1.75	1.60	2.8
b) Mat Credit		-	-	-	-
Net Profit/(Loss) for the period/year	15.54	32.20	35.26	47.74	66.60
Other comprehensive income (net of tax)					
Items that will not be reclassified to profit or loss:		-	5	-	5
Total other comprehensive income			5	-	5
Total comprehensive income for the period/year (VII+VIII)	15.54	32.20	40.19	47.74	71.53
Paid-up equity share capital (face value of the share shall be indicated)	1,000.55	1,000.55	1,000.55	1,000.55	1,000.55
Other equity (excluding revaluation reserve)	685.41	656.61	637.51	685.41	637.51
EPS in Rs. (Face Value of Rs.10/- each)*					
-Basic	0.16	0.32	0.35	0.48	0.67
-Diluted	0.16	0.32	0.35	0.32	0.67
Notes:					



1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 11.11.2022 after being reviewed by the Audit Committee.	
2. The company is having single segment in accordance with IND AS 108 "operating segments" . and therefore segment reporting is not applicable to the Company.	
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.	

Date 11.11.2022

Place : Mohali



For Ajooni Biotech Limited
 Jasjit Singh
 Managing Director ★
 DIN:
 01937631

Statement of Assets and Liabilities
For the Half Year ended on 30th
September 2022

<u>PARTICULARS</u>	<u>30th Sep 2022</u>	<u>in Rs. 31st March 2022</u>
<u>I. ASSETS</u>		
<u>(1) Non - Current Assets</u>		
a) Property, Plant and Equipment	67,564,244	62,052,358
b) Financial Assets		
(1) Non-Current Investments	9,590,692	7,038,909
c) Deffered Tax Asset	1,958,500	1,818,383
<u>(2) Current Assets</u>		
a) Inventories	44,766,589	58,817,040
b) Financial Assets		
(1) Cash & Cash Equivalent	1,823,880	573,855
(2) Short Term Loans and advances	15,500,136	21,471,815
(3) Trade Receivables	132,874,747	138,402,877

TOTAL Rs.	274,078,789	290,175,237
------------------	--------------------	--------------------

II EQUITY AND LIABILITIES

<u>(1) Equity</u>		
a) Equity Share Capital	100,055,820	100,055,820
b) Other Equity	68,541,900	63,767,836
<u>(2) Non-Current Liabilities</u>		

a) Financial Liabilities

(1) Borrowings	23,639,042	25,763,844
----------------	------------	------------

(3) Current Liabilities

a) Financial Liabilities

(1) Borrowings	43,539,917	27,740,793
----------------	------------	------------

(2) Trade Payables	33,415,770	67,991,141
--------------------	------------	------------

b) Other Current
Liabilities

3,265,239	379,543
-----------	---------

c) Current tax liabilities
(Net)

1,621,100	4,476,260
-----------	-----------

TOTAL Rs.	274,078,788	290,175,237
------------------	--------------------	--------------------

Date: 11.11.2022


Place: Mohali

For Ajooni Biotech Limited

Jasjot Singh

Managing Director

DIN: 01937631





Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. Ajooni Biotech Limited having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30th SEPTEMBER 2022 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.
Chartered Accountants

CA Konica Madan
Partner

M.No 547759

Date : 11.11.2022

UDIN : 22547759BCUHB05419.

